Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, February 18, 2022
[ Fri, Feb 18th 2022
] - WOPRAI
[ Fri, Feb 18th 2022
] - WOPRAI
[ Fri, Feb 18th 2022
] - WOPRAI
[ Fri, Feb 18th 2022
] - WOPRAI
[ Fri, Feb 18th 2022
] - WOPRAI
[ Fri, Feb 18th 2022
] - WOPRAI
[ Fri, Feb 18th 2022
] - WOPRAI
[ Fri, Feb 18th 2022
] - WOPRAI
[ Fri, Feb 18th 2022
] - WOPRAI
[ Fri, Feb 18th 2022
] - WOPRAI
[ Fri, Feb 18th 2022
] - WOPRAI
[ Fri, Feb 18th 2022
] - WOPRAI
[ Fri, Feb 18th 2022
] - WOPRAI
[ Fri, Feb 18th 2022
] - WOPRAI
[ Fri, Feb 18th 2022
] - WOPRAI
[ Fri, Feb 18th 2022
] - WOPRAI
[ Fri, Feb 18th 2022
] - WOPRAI
[ Fri, Feb 18th 2022
] - WOPRAI
[ Fri, Feb 18th 2022
] - WOPRAI
[ Fri, Feb 18th 2022
] - WOPRAI
[ Fri, Feb 18th 2022
] - WOPRAI
[ Fri, Feb 18th 2022
] - WOPRAI
[ Fri, Feb 18th 2022
] - WOPRAI
[ Fri, Feb 18th 2022
] - WOPRAI
[ Fri, Feb 18th 2022
] - WOPRAI
[ Fri, Feb 18th 2022
] - WOPRAI
[ Fri, Feb 18th 2022
] - WOPRAI
[ Fri, Feb 18th 2022
] - WOPRAI
[ Fri, Feb 18th 2022
] - WOPRAI
Balaji Prasad Maintained (TEVA) at Hold with Decreased Target to $11 on, Feb 18th, 2022
Balaji Prasad of Barclays, Maintained "Teva Pharmaceutical Industries Limited" (TEVA) at Hold with Decreased Target from $13 to $11 on, Feb 18th, 2022.
Balaji has made no other calls on TEVA in the last 4 months.
There are 2 other peers that have a rating on TEVA. Out of the 2 peers that are also analyzing TEVA, all agree with Balaji's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Jasper Hellweg of "Argus Research" Downgraded from Strong Buy to Hold on, Thursday, January 27th, 2022
- Elliot Wilbur of "Raymond James" Downgraded from Buy to Hold on, Thursday, October 28th, 2021
